Skip to main
CMPS

COMPASS Pathways (CMPS) Stock Forecast & Price Target

COMPASS Pathways (CMPS) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 60%
Buy 30%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Compass Pathways is well-positioned for success in the near-term, with a cash runway until 2028 and an accelerated launch path that is expected to offset any potential increase in commercial spending. Additionally, the company's focus on treatment-resistant depression and its strong commercial infrastructure strategy give it a competitive advantage in the space. Management's emphasis on potential strategic partnerships and its confident stance on defending its intellectual property position are also positive indicators for the company's future success.

Bears say

Compass Pathways is facing a challenging market as a growing number of competitors enter the psychedelic medicine field, with many different approaches and treatments for mental health disorders. While the company has invested in building capabilities for their specific therapy, the expanding landscape may make it difficult for them to stand out and compete. Additionally, recent regulatory changes may open the door for other companies to enter the market, potentially creating further competition and pricing pressures for Compass Pathways' treatment. However, the company's Phase 3 trials and growing network of certified sites could give them an advantage in the near-term, and their focus on treatment-resistant depression could work in their favor as a unique offering. Investors should closely monitor the outcome of ongoing clinical trials and any potential changes in the regulatory landscape, which could significantly impact the company's future success.

COMPASS Pathways (CMPS) has been analyzed by 10 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 30% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About COMPASS Pathways (CMPS) Forecast

Analysts have given COMPASS Pathways (CMPS) a Buy based on their latest research and market trends.

According to 10 analysts, COMPASS Pathways (CMPS) has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

COMPASS Pathways (CMPS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.